Lasers in surgery and medicine · 2026
Fractional CO2 Laser Combined With Topical Corticosteroids for Vulvar Lichen Simplex Chronicus: An Observational Study From an 8-Year Single-Center Experience.
СтатьяНаблюдательное исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Wei Dongmei, Meng Jian, Zhu Yanjun, Li Qiao, Wang Yajing, Chen Yueyue, Niu Xiaoyu
Аннотация
BACKGROUND: Vulvar lichen simplex chronicus (VLSC) is a chronic inflammatory dermatosis that remains difficult to manage long term. Fractional CO2 laser (FxCO2) combined with topical corticosteroids (TCs) has emerged as a potential therapeutic strategy; however, high-quality long-term evidence remains limited.
OBJECTIVE: To evaluate the long-term efficacy and safety of FxCO2 combined with TC in patients with VLSC.
STUDY DESIGN: This retrospective single-center study included 172 patients with biopsy-confirmed VLSC treated between 2016 and 2024. All patients received at least one FxCO2 + TC treatment session. Primary outcomes included pruritus improvement, recurrence, and subjective symptom relief. Secondary outcomes assessed patient satisfaction, treatment adherence, and adverse events.
RESULTS: FxCO2 combined with TC treatment was effective, achieving an initial pruritus improvement rate of 90.12% (155/172). Subjective symptom improvement was reported by 91.86% (158/172) of patients, and patient satisfaction was 88.95% (153/172). Among those who improved, 50.58% (80/155) achieved improvement after 3 treatments, and the median duration of improvement was 18.0 months (range, 12-54 months). The recurrence rate was 14.84% (23/155), with a median time to recurrence of 36.0 months (range, 12-60 months). Adverse events occurred in 15.70% (27/172) of patients, with dryness being the most common (6.40%, 11/172). No clinical signs of deterioration or atypical progression were noted throughout the follow-up.
CONCLUSION: FxCO2 combined with TC treatment is effective and well tolerated in women with VLSC, providing long-term symptom relief with low recurrence and acceptable safety. This combined approach may represent a promising therapeutic option for managing intense pruritus associated with VLSC.
OBJECTIVE: To evaluate the long-term efficacy and safety of FxCO2 combined with TC in patients with VLSC.
STUDY DESIGN: This retrospective single-center study included 172 patients with biopsy-confirmed VLSC treated between 2016 and 2024. All patients received at least one FxCO2 + TC treatment session. Primary outcomes included pruritus improvement, recurrence, and subjective symptom relief. Secondary outcomes assessed patient satisfaction, treatment adherence, and adverse events.
RESULTS: FxCO2 combined with TC treatment was effective, achieving an initial pruritus improvement rate of 90.12% (155/172). Subjective symptom improvement was reported by 91.86% (158/172) of patients, and patient satisfaction was 88.95% (153/172). Among those who improved, 50.58% (80/155) achieved improvement after 3 treatments, and the median duration of improvement was 18.0 months (range, 12-54 months). The recurrence rate was 14.84% (23/155), with a median time to recurrence of 36.0 months (range, 12-60 months). Adverse events occurred in 15.70% (27/172) of patients, with dryness being the most common (6.40%, 11/172). No clinical signs of deterioration or atypical progression were noted throughout the follow-up.
CONCLUSION: FxCO2 combined with TC treatment is effective and well tolerated in women with VLSC, providing long-term symptom relief with low recurrence and acceptable safety. This combined approach may represent a promising therapeutic option for managing intense pruritus associated with VLSC.